Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0507A, dorzolamide timolol · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MK0507A, dorzolamide hydrochloride (+) timolol maleate | DRUG | - |
| Comparator: timolol maleate | DRUG | - |
| Duration of Treatment: Part 1) 6 wk timolol maleate run in | DRUG | - |
| Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds | DRUG | - |
Inclusion Criteria: * Patients with glaucoma or ocular hypertension Exclusion Criteria: * Other eye conditions * Poor vision * Recent eye surgery * Use of contact lenses * Nursing or pregnant women * Use of some other selected medications * Drug or alcohol abuse * Asthma * Slow heart beat * Aller...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |